BaroFold applies its Pressure Enabled Protein Manufacturing (PreEMT™) technology to improve the tolerability, efficacy and safety of a wide variety of protein therapeutics for bio-pharmaceutical companies, research institutions, and government agencies. PreEMT employs high pressure to disaggregate and refold proteins, which may have a significant impact on the quality of these biotherapeutics by improving their activity, homogeneity and safety. BaroFold also helps companies create novel protein therapeutics, accelerate therapeutic protein development, manufacture follow-on biologics and enable life-cycle management of protein therapeutics.
BaroFold was founded in 2009 by Dr. Matt Seefeldt and Matt Brewer through the acquisitions of a new company and is based on the patented PreEMT technology invented at the University of Colorado in the laboratories of Dr. Ted Randolph and Dr. John Carpenter. The Company is located at the Fitzsimons Bioscience Park in Aurora, CO and enjoys ample access to talented researchers within the biotech corridor between Denver and Boulder. Our facility houses state of the art high pressure equipment that can accommodate research studies from proof-of-concept through 10L non-GMP material generation.
PreEMT is a patented technology that employs high pressure for the disaggregation and controlled refolding of proteins to their native structures at yields and efficiencies not achievable using existing technologies. PreEMT results in the dissolution of protein aggregates which may have a significant impact on the quality of protein therapeutics by improving the activity, homogeneity and stability.
BaroFold's technology exposes aggregated protein at any stage in the manufacturing process to elevated pressure, at which water is forced between non-native protein interactions, resulting in disaggregation. The high pressures used by PreEMT forces the protein into its most compact form, usually its native state. Biologically active, native protein is recovered within hours at yields as high as 100%, even at high protein concentrations.
PreEMT can be applied to a wide variety of therapeutic proteins (existing or novel), including single polypeptide chains, multimeric protein complexes with and without disulfide bridges, and protein crystals. PreEMT can be utilized in the refolding of recombinant proteins produced in mammalian cells, yeast or E. coli. PreEMT has significant utility in the refolding of recombinant proteins produced in E. coli at high expression levels as inclusion bodies, most particularly antibody fragments and toxic proteins. In addition, PreEMT may be used to reduce aggregate levels in bulk or final formulations of all classes of therapeutic proteins, thus improving product safety profiles by reducing the risk of aggregate-induced immune responses.
PreEMT is readily scaleable and is practical for the standard manufacturing process for recombinant proteins. Importantly, PreEMT has the potential to substantially reduce the cost of manufacturing due to its increased efficiency and high yield of refolding.
BaroFold is leveraging PreEMT as a valuable tool to help its industry partners create novel protein therapeutics, accelerate therapeutic protein development, manufacture follow-on biologics, and enable life-cycle management of protein therapeutics.
Seefeldt, M. B., Rosendahl, M. S., Cleland, J. L. & Hesterberg, L. K. Application of high hydrostatic pressure to dissociate aggregates and refold proteins. Current pharmaceutical biotechnology 10, 447-455 (2009).
BaroFold Inc. has not received any reviews.
BaroFold Inc. has not received any endorsements.